| Literature DB >> 35066162 |
Yura K Ko1, Yuki Furuse2, Kota Ninomiya3, Kanako Otani4, Hiroki Akaba5, Reiko Miyahara6, Tadatsugu Imamura7, Takeaki Imamura8, Alex R Cook9, Mayuko Saito10, Motoi Suzuki11, Hitoshi Oshitani12.
Abstract
OBJECTIVES: Super-spreading events caused by overdispersed secondary transmission are crucial in the transmission of COVID-19. However, the exact level of overdispersion, demographics, and other factors associated with secondary transmission remain elusive. In this study, we aimed to elucidate the frequency and patterns of secondary transmission of SARS-CoV-2 in Japan.Entities:
Keywords: COVID-19; Dispersion parameter; Overdispersion; Secondary transmission; Super-spreading events
Mesh:
Year: 2022 PMID: 35066162 PMCID: PMC8772065 DOI: 10.1016/j.ijid.2022.01.036
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 12.074
Figure 1The epidemiologic curve of COVID-19 cases in Japan by reported date between January 2020 and August 2020. The whole period was divided into 4 phases (phases 1–4) on the basis of the epidemic trend.
Figure 2a) The observed distribution of the number of secondary cases from total 16,471 primary cases for the entire period. The number above each bar indicates the absolute number of secondary cases. Estimated reproductive number (R) and overdispersion parameter (k) by fitting the negative binomial distribution are also shown. b) Joint estimates of k and R in each phase. The posterior distributions of each parameter are plotted in the outer margin of each axis.
The estimated effective reproductive number (R), overdispersion parameter (k), proportion of infectious cases responsible for 80% of all cases, and proportion of cases that did not generate any secondary transmissions stratified by the phase and age group.
| Whole Period | All | 16471 | 0.47 (0.45–0.49) | 0.23 (0.22–0.25) | 13.3% (12.8%–13.9%) | 77.2% (76.3%–78.1%) |
| 0-19 | 847 | 0.36 (0.30–0.43) | 0.22 (0.17–0.29) | 12.1% (9.9%–14.6%) | 80.7% (76.8%–84%) | |
| 20-39 | 7647 | 0.41 (0.38–0.43) | 0.21 (0.19–0.23) | 12.1% (11.4%–12.9%) | 79.7% (78.4%–80.9%) | |
| 40-69 | 5832 | 0.52 (0.49–0.55) | 0.29 (0.26–0.32) | 15.4% (14.4%–16.3%) | 74.1% (72.6%–75.8%) | |
| 70- | 1996 | 0.62 (0.55–0.69) | 0.21 (0.18–0.24) | 13% (11.6%–14.5%) | 74.9% (72.1%–77.5%) | |
| Phase1 | All | 2415 | 0.53 (0.48–0.58) | 0.21 (0.18–0.24) | 12.6% (11.4%–13.9%) | 76.9% (74.4%–79.1%) |
| 0-19 | 62 | 0.24 (0.11–0.45) | 0.42 (0.12– | 12.6% (5.4%–27.3%) | 82.6% (63.7%–92.4%) | |
| 20-39 | 762 | 0.35 (0.29–0.42) | 0.24 (0.18–0.33) | 12.4% (10%–15.3%) | 80.6% (76.3%–84.2%) | |
| 40-69 | 1233 | 0.57 (0.50–0.65) | 0.22 (0.19–0.27) | 13.3% (11.6%–15.3%) | 75.3% (71.6%–78.4%) | |
| 70- | 343 | 0.83 (0.62–1.06) | 0.20 (0.15–0.28) | 13.9% (10.7%–17.6%) | 72% (64.7%–78.3%) | |
| Phase2 | All | 1738 | 0.37 (0.32–0.42) | 0.19 (0.16–0.23) | 11.2% (9.7%–12.9%) | 81.5% (78.8%–83.9%) |
| 0-19 | 44 | 0.2 (0.07–0.43) | 0.53 (0.08– | 11.8% (3.5%–26.4%) | 84.1% (64.9%–95.1%) | |
| 20-39 | 471 | 0.24 (0.17–0.31) | 0.16 (0.10–0.24) | 8.8% (6.2%–11.9%) | 86.4% (81.9%–90.4%) | |
| 40-69 | 823 | 0.44 (0.36–0.53) | 0.20 (0.15–0.26) | 11.9% (9.7%–14.5%) | 79.2% (74.8%–83%) | |
| 70- | 364 | 0.39 (0.29–0.5) | 0.24 (0.16–0.36) | 12.9% (9.5%–16.9%) | 79.3% (73.1%–84.7%) | |
| Phase3 | All | 6397 | 0.50 (0.47–0.53) | 0.25 (0.23–0.27) | 13.9% (13.1%–14.9%) | 76% (74.5%–77.4%) |
| 0-19 | 443 | 0.45 (0.36–0.57) | 0.26 (0.18–0.38) | 14% (10.7%–18.1%) | 76.9% (70.5%–82.1%) | |
| 20-39 | 3795 | 0.47 (0.44–0.51) | 0.21 (0.19–0.24) | 12.5% (11.5%–13.6%) | 78% (76.1%–79.8%) | |
| 40-69 | 1625 | 0.58 (0.52–0.65) | 0.32 (0.27–0.38) | 16.5% (14.9%–18.5%) | 71.8% (68.6%–74.6%) | |
| 70- | 455 | 0.49 (0.39–0.59) | 0.34 (0.25–0.5) | 16.4% (13%–20.5%) | 73.8% (67.6%–79.1%) | |
| Phase4 | All | 5921 | 0.44 (0.42–0.48) | 0.25 (0.23–0.28) | 13.7% (12.8%–14.7%) | 77.4% (75.8%–78.9%) |
| 0-19 | 298 | 0.27 (0.17–0.38) | 0.16 (0.09–0.28) | 9.1% (5.9%–13.6%) | 85.5% (78.9%–90.7%) | |
| 20-39 | 2619 | 0.36 (0.32–0.39) | 0.23 (0.19–0.27) | 12.1% (10.8%–13.6%) | 80.7% (78.5%–82.7%) | |
| 40-69 | 2151 | 0.48 (0.44–0.53) | 0.39 (0.33–0.46) | 17.3% (15.6%–19.2%) | 73.1% (70.3%–75.7%) | |
| 70- | 834 | 0.70 (0.58–0.82) | 0.19 (0.16–0.24) | 12.9% (10.9%–15.2%) | 74.6% (70.1%–78.5%) |
Prop80% is the proportion of cases responsible for 80% of all cases.
Prop0% is the proportion of cases that did not generate any secondary transmissions.
Figure 3Relationship between primary and secondary cases by age group and gender for each phase. The color scale shows the proportion of observed total transmission pairs in each phase. Note that the color scales are different between phases 1, 2, and 4 and phases 3.
F, female; M, male.
Figure 4OR and aOR by comparing between a) the proportion of cases that generated ≥1 secondary transmissions and that of cases with no secondary transmission and comparing between b) the proportion of cases that generated ≥5 secondary transmissions and that of cases that generated 1–4 secondary transmissions. ORs were calculated between phases, age group, gender, presence of symptoms, and days from onset to confirmation, with phase 3, those aged 20–29 years, male gender, symptomatic at confirmation, and within 2 days from onset to confirmation as the reference for each category.
OR, odds ratio; aOR, adjusted odds ratio; adjusted for phase, age, presence of symptoms at confirmation, and days between onset and confirmation.